{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:22:54Z","timestamp":1794565374122,"version":"4.9.1"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.diabres.2026.113288","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:59:40Z","timestamp":1777647580000},"page":"113288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["DPP-4 inhibitors in current diabetes care: their foundational role in treating to target"],"prefix":"10.1016","volume":"237","author":[{"given":"Angelo","family":"Avogaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Fiaccadori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10397","key":"10.1016\/j.diabres.2026.113288_b0005","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","author":"Ong","year":"2023","journal-title":"The Lancet"},{"issue":"11","key":"10.1016\/j.diabres.2026.113288_b0010","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of Hyperglycemia in type 2 diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"issue":"15","key":"10.1016\/j.diabres.2026.113288_b0015","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.diabres.2026.113288_b0020","doi-asserted-by":"crossref","first-page":"706","DOI":"10.2337\/dc16-1943","article-title":"Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies","volume":"40","author":"Azoulay","year":"2017","journal-title":"Diabetes Care"},{"issue":"20","key":"10.1016\/j.diabres.2026.113288_b0025","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.jacc.2025.08.027","article-title":"Cardiovascular effects and tolerability of GLP-1 receptor agonists","volume":"86","author":"Galli","year":"2025","journal-title":"JACC"},{"issue":"25","key":"10.1016\/j.diabres.2026.113288_b0030","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1016\/j.jacc.2023.04.034","article-title":"Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations","volume":"81","author":"Usman","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.diabres.2026.113288_b0035","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s12933-022-01712-4","article-title":"Management of type 2 diabetes with a treat-to-benefit approach improved long-term cardiovascular outcomes under routine care","volume":"21","author":"Morieri","year":"2022","journal-title":"CardioVasc Diabetol"},{"issue":"6","key":"10.1016\/j.diabres.2026.113288_b0040","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.2337\/dc07-0233","article-title":"Dipeptidyl peptidase-4 inhibitors","volume":"30","author":"Ahr\u00e9n","year":"2007","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.diabres.2026.113288_b0045","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005892","article-title":"A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients","volume":"5","author":"Esposito","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.diabres.2026.113288_b0050","article-title":"Type 2 diabetes mellitus \u2013 conventional therapies and future perspectives in innovative treatment","volume":"42","author":"Gieroba","year":"2025","journal-title":"Biochem Biophys Rep"},{"issue":"11","key":"10.1016\/j.diabres.2026.113288_b0055","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1007\/s00125-006-0416-z","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus","volume":"49","author":"Raz","year":"2006","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.diabres.2026.113288_b0060","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.metabol.2012.09.004","article-title":"A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients","volume":"62","author":"Satoh-Asahara","year":"2013","journal-title":"Metabolism"},{"issue":"21","key":"10.1016\/j.diabres.2026.113288_b0065","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1161\/CIRCULATIONAHA.111.041418","article-title":"Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis","volume":"124","author":"Shah","year":"2011","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.diabres.2026.113288_b0070","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.2337\/dc20-1521","article-title":"Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and COVID-19: a multicenter, case-control, retrospective, observational study","volume":"43","author":"Solerte","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2026.113288_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177708","article-title":"Sitagliptin reduces cytokine-induced \u03b2-cell apoptosis in prediabetes: a six-month interventional study","volume":"999","author":"Ayash","year":"2025","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"10.1016\/j.diabres.2026.113288_b0080","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.2337\/db07-0697","article-title":"Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice","volume":"56","author":"Flock","year":"2007","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.diabres.2026.113288_b0085","doi-asserted-by":"crossref","first-page":"122","DOI":"10.14740\/jocmr4078","article-title":"Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin on muscle mass and the muscle\/fat ratio in patients with type 2 diabetes","volume":"12","author":"Ishii","year":"2020","journal-title":"J Clin Med Res"},{"issue":"10","key":"10.1016\/j.diabres.2026.113288_b0090","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.2337\/dc14-0865","article-title":"The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications","volume":"37","author":"Avogaro","year":"2014","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.diabres.2026.113288_b0095","doi-asserted-by":"crossref","first-page":"F963","DOI":"10.1152\/ajprenal.00259.2012","article-title":"Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice","volume":"303","author":"Rieg","year":"2012","journal-title":"Am J Physiol-Ren Physiol"},{"issue":"6","key":"10.1016\/j.diabres.2026.113288_b0100","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.2337\/db13-1029","article-title":"Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic Regimen","volume":"63","author":"Kanasaki","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2026.113288_b0105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijcard.2015.11.180","article-title":"Sitagliptin plus granulocyte colony-stimulating factor in patients suffering from acute myocardial infarction: a double-blind, randomized placebo-controlled trial of efficacy and safety (SITAGRAMI trial)","volume":"205","author":"Brenner","year":"2016","journal-title":"Int JCardiol"},{"issue":"4","key":"10.1016\/j.diabres.2026.113288_b0110","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ahj.2011.08.004","article-title":"EXamination of CArdiovascular OutcoMes with AlogliptIN versus standard of CarE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE)","volume":"162","author":"White","year":"2011","journal-title":"Am Heart J"},{"issue":"14","key":"10.1016\/j.diabres.2026.113288_b0115","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.diabres.2026.113288_b0120","doi-asserted-by":"crossref","first-page":"494","DOI":"10.2337\/dc16-1135","article-title":"Assessing the safety of sitagliptin in older participants in the trial evaluating cardiovascular outcomes with sitagliptin (TECOS)","volume":"40","author":"Bethel","year":"2017","journal-title":"Diabetes Care"},{"issue":"9982","key":"10.1016\/j.diabres.2026.113288_b0125","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.diabres.2026.113288_b0130","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"J Am Med Assoc"},{"issue":"12","key":"10.1016\/j.diabres.2026.113288_b0135","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of Linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial","volume":"322","author":"Rosenstock","year":"2019","journal-title":"J Am Med Assoc"},{"issue":"3","key":"10.1016\/j.diabres.2026.113288_b0140","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.diabres.2026.113288_b0145","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.2337\/dc16-1415","article-title":"Effect of Sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: outcomes from TECOS","volume":"39","author":"Cornel","year":"2016","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.diabres.2026.113288_b0150","first-page":"1587","article-title":"Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS","volume":"19","author":"Engel","year":"2017","journal-title":"DiabetesObes Metab"},{"issue":"12","key":"10.1016\/j.diabres.2026.113288_b0155","first-page":"1061","article-title":"Longer term safety of dipeptidyl peptidase\u20104 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta\u2010analysis","volume":"14","author":"Goo\u00dfen","year":"2012","journal-title":"DiabetesObes Metab"},{"issue":"9","key":"10.1016\/j.diabres.2026.113288_b0160","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2165\/11532980-000000000-00000","article-title":"Dipeptidylpeptitase-4 inhibitors (Gliptins): focus on drug-drug interactions","volume":"49","author":"Scheen","year":"2010","journal-title":"Clin Pharmacokinet"},{"issue":"15","key":"10.1016\/j.diabres.2026.113288_b0165","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.3390\/ijerph16152720","article-title":"The role of DPP-4 inhibitors in the treatment algorithm of type 2 diabetes mellitus: when to select, what to expect","volume":"16","author":"Makrilakis","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.diabres.2026.113288_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154295","article-title":"The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes","volume":"109","author":"Stoian","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2026.113288_b0175","doi-asserted-by":"crossref","DOI":"10.1007\/s00592-025-02569-1","article-title":"Italian guidelines for the treatment of type 1 diabetes","author":"Pintaudi","year":"2025","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.diabres.2026.113288_b0180","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2147\/VHRM.S1944","article-title":"Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin","volume":"4","author":"Ahren","year":"2008","journal-title":"Vasc Health Risk Manag"},{"issue":"2","key":"10.1016\/j.diabres.2026.113288_b0185","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1185\/030079908X260925","article-title":"Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes","volume":"24","author":"Raz","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"10.1016\/j.diabres.2026.113288_b0190","first-page":"1128","article-title":"Double\u2010blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: the CompoSIT\u2010M study","volume":"21","author":"Frias","year":"2019","journal-title":"DiabetesObes Metab"},{"issue":"10208","key":"10.1016\/j.diabres.2026.113288_b0195","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(19)32131-2","article-title":"Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial","volume":"394","author":"Matthews","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2026.113288_b0200","first-page":"39","article-title":"Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality","volume":"117","author":"Eriksson","year":"2016","journal-title":"DiabetesResClin Pract"},{"issue":"3","key":"10.1016\/j.diabres.2026.113288_b0205","first-page":"231","article-title":"Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: the ODYSSEE observational study","volume":"41","author":"Valensi","year":"2015","journal-title":"DiabetesMetab"},{"issue":"1","key":"10.1016\/j.diabres.2026.113288_b0210","first-page":"46","article-title":"Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second\u2010line glucose\u2010lowering therapy: the global DISCOVER study","volume":"25","author":"Charbonnel","year":"2023","journal-title":"DiabetesObes Metab"},{"issue":"3","key":"10.1016\/j.diabres.2026.113288_b0215","doi-asserted-by":"crossref","first-page":"740","DOI":"10.2337\/dc13-0467","article-title":"\u2018Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: A 24-week, multicenter, randomized, double-blind, placebo-controlled study\u2019","volume":"37","author":"Jabbour","year":"2024","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.diabres.2026.113288_b0220","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/00325481.2015.1044756","article-title":"Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus","volume":"127","author":"Guthrie","year":"2015","journal-title":"Postgrad Med"},{"issue":"5","key":"10.1016\/j.diabres.2026.113288_b0225","first-page":"1111","article-title":"Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial","volume":"20","author":"Pratley","year":"2018","journal-title":"DiabetesObes Metab"},{"issue":"3","key":"10.1016\/j.diabres.2026.113288_b0230","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc14-2364","article-title":"Combination of Empagliflozin and Linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin","volume":"38","author":"DeFronzo","year":"2015","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.diabres.2026.113288_b0235","first-page":"740","article-title":"Dipeptidyl peptidase\u20104 inhibitors moderate the risk of genitourinary tract infections associated with sodium\u2010glucose co\u2010transporter\u20102 inhibitors","volume":"20","author":"Fadini","year":"2018","journal-title":"DiabetesObes Metab"},{"issue":"8","key":"10.1016\/j.diabres.2026.113288_b0240","first-page":"1972","article-title":"SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: a systematic review and meta-analysis","volume":"20","author":"Li","year":"2018","journal-title":"DiabetesObes Metab"},{"issue":"10","key":"10.1016\/j.diabres.2026.113288_b0245","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40261-013-0107-8","article-title":"Saxagliptin Add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy","volume":"33","author":"Barnett","year":"2013","journal-title":"Clin Drug Investig"},{"issue":"2","key":"10.1016\/j.diabres.2026.113288_b0250","first-page":"127","article-title":"A randomized clinical trial to evaluate the efficacy and safety of co-administration of Sitagliptin with intensively titrated insulin glargine","volume":"6","author":"Mathieu","year":"2015","journal-title":"DiabetesTher"},{"issue":"4","key":"10.1016\/j.diabres.2026.113288_b0255","first-page":"781","article-title":"Double\u2010blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase\u20104 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: the CompoSIT\u2010I Study","volume":"21","author":"Roussel","year":"2019","journal-title":"DiabetesObes Metab"},{"key":"10.1016\/j.diabres.2026.113288_b0260","article-title":"Profiles of sulfonylurea use in Diabetes Mellitus type 2: an analysis of clinical practice over the last 10 years","volume":"214","author":"Baccetti","year":"2024","journal-title":"DiabetesResClin Pract"},{"issue":"2","key":"10.1016\/j.diabres.2026.113288_b0265","first-page":"160","article-title":"Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double\u2010blind, non\u2010inferiority trial","volume":"13","author":"Arechavaleta","year":"2011","journal-title":"DiabetesObes Metab"},{"issue":"9902","key":"10.1016\/j.diabres.2026.113288_b0270","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(13)61500-7","article-title":"Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Barnett","year":"2013","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.diabres.2026.113288_b0275","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afae259","article-title":"Systematic review of guideline recommendations for older and frail adults with type 2 diabetes mellitus","volume":"53","author":"Bolt","year":"2024","journal-title":"Age Ageing"},{"key":"10.1016\/j.diabres.2026.113288_b0280","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee et al., \u201813. Older Adults: Standards of Care in Diabetes\u20142025\u2019, Diabetes Care, vol. 48, no. Supplement_1, pp. S266\u2013S282, Jan. 2025, doi: 10.2337\/dc25-S013.","DOI":"10.2337\/dc25-S013"},{"issue":"5","key":"10.1016\/j.diabres.2026.113288_b0285","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jamda.2017.11.002","article-title":"A randomized controlled study comparing a DPP4 inhibitor (Linagliptin) AND BASAL INSULIN (Glargine) in patients with type 2 diabetes in long-term care and skilled nursing facilities: linagliptin-LTC trial","volume":"19","author":"Umpierrez","year":"2018","journal-title":"J Am Med Dir Assoc"},{"issue":"6","key":"10.1016\/j.diabres.2026.113288_b0290","doi-asserted-by":"crossref","first-page":"980","DOI":"10.4158\/EP13148.OR","article-title":"Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea","volume":"19","author":"Liu","year":"2013","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.diabres.2026.113288_b0295","first-page":"525","article-title":"Neuroprotective properties of DPP \u20104i: a therapeutic target for dementia prevention in elderly diabetic patients?","volume":"14","author":"Umemura","year":"2023","journal-title":"J DiabetesInvestig"},{"issue":"4","key":"10.1016\/j.diabres.2026.113288_b0300","first-page":"403","article-title":"Sitagliptin, a dipeptidyl peptidase\u20104 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline","volume":"17","author":"Gault","year":"2015","journal-title":"DiabetesObes Metab"},{"issue":"4","key":"10.1016\/j.diabres.2026.113288_b0305","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/brain\/awab015","article-title":"Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson\u2019s disease","volume":"144","author":"Jeong","year":"2021","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.diabres.2026.113288_b0310","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2174\/1573399810666140918121022","article-title":"Effects of the antidiabetic drugs on the age-related atrophy and sarcopenia associated with diabetes type II","volume":"10","author":"Cetrone","year":"2014","journal-title":"Curr Diabetes Rev"},{"issue":"10","key":"10.1016\/j.diabres.2026.113288_b0315","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jamda.2016.04.016","article-title":"Sarcopenia in elderly diabetic patients: role of dipeptidyl peptidase 4 inhibitors","volume":"17","author":"Rizzo","year":"2016","journal-title":"J Am Med Dir Assoc"},{"issue":"2","key":"10.1016\/j.diabres.2026.113288_b0320","doi-asserted-by":"crossref","first-page":"e2957","DOI":"10.1002\/dmrr.2957","article-title":"Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes","volume":"34","author":"Bouchi","year":"2018","journal-title":"Diabetes Metab Res Rev"},{"issue":"2","key":"10.1016\/j.diabres.2026.113288_b0325","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.atherosclerosis.2012.12.018","article-title":"Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors","volume":"227","author":"Barbieri","year":"2013","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.diabres.2026.113288_b0330","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.clinthera.2024.06.015","article-title":"Pancreatitis and pancreatic cancer risk among patients with type 2 diabetes receiving dipeptidyl peptidase 4 inhibitors: an updated meta-analysis of randomized controlled trials","volume":"46","author":"Tuersun","year":"2024","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.diabres.2026.113288_b0335","doi-asserted-by":"crossref","first-page":"Oct","DOI":"10.17925\/EE.2024.20.2.5","article-title":"New insights into the pleiotropic actions of dipeptidyl peptidase-4 inhibitors beyond glycaemic control","volume":"20","author":"Mangoura","year":"2024","journal-title":"TouchREVIEWS Endocrinol"},{"issue":"6","key":"10.1016\/j.diabres.2026.113288_b0340","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.xkme.2021.07.007","article-title":"Dipeptidyl peptidase-4 inhibitors and diabetic kidney disease: a narrative review","volume":"3","author":"Daza-Arnedo","year":"2021","journal-title":"Kidney Med"},{"issue":"1","key":"10.1016\/j.diabres.2026.113288_b0345","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12944-024-02132-x","article-title":"Effect of DPP-4i inhibitors on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Gong","year":"2024","journal-title":"Lipids Health Dis"},{"issue":"9","key":"10.1016\/j.diabres.2026.113288_b0350","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1093\/ndt\/gfad015","article-title":"Factors associated with kalemia in renal disease","volume":"38","author":"Granal","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.diabres.2026.113288_b0355","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2215\/CJN.09380822","article-title":"Kidney-protective effects of SGLT2 inhibitors","volume":"18","author":"Palmer","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.diabres.2026.113288_b0360","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1007\/s40620-024-02048-w","article-title":"The influence of insulin and incretin-based therapies on renal tubular transport","volume":"37","author":"Rosati","year":"2024","journal-title":"J Nephrol"},{"key":"10.1016\/j.diabres.2026.113288_b0365","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.2147\/DMSO.S445114","article-title":"Efficacy and safety of the utilization of dipeptidyl peptidase IV inhibitors in diabetic patients with chronic kidney disease: a meta-analysis of randomized clinical trials","volume":"17","author":"Mahzari","year":"2024","journal-title":"DiabetesMetab Syndr Obes"},{"issue":"5","key":"10.1016\/j.diabres.2026.113288_b0370","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2215\/CJN.10180916","article-title":"Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function","volume":"12","author":"Petrykiv","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.diabres.2026.113288_b0375","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2147\/DDDT.S32331","article-title":"A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment","author":"Bain","year":"2013","journal-title":"Drug Des Devel Ther"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726002081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726002081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:22:31Z","timestamp":1794561751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726002081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":75,"alternative-id":["S0168822726002081"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113288","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DPP-4 inhibitors in current diabetes care: their foundational role in treating to target","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113288","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113288"}}